Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today
Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today. The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.691 billion. The company did take a hit in this result due to the one-off US antitrust class action litigation settlement of US$64 million. CSL will pay a half year dividend of US$0.53. The said it expects FY14 after tax profit growth of around 7% and CSL will continue its current A$950 million share buyback that is now 22% completed. Watch full report here:
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
No areas of expertise